CIK 0001806310 · Non-accelerated filer<br>Smaller reporting company
Taysha Gene Therapies, Inc.
Sign in to watch- Ticker
- TSHA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843199512
- Phone
- (214) 612-0000
- Business address
- 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-17 | Nagendran Sukumar Director | Grant or award · Stock Option (right to buy) | +15,500 | 15,500 | ||
| 2022-06-17 | Nolan Sean P. Director | Grant or award · Stock Option (right to buy) | +15,500 | 15,500 | ||
| 2022-06-17 | Reape Kathleen Director | Grant or award · Stock Option (right to buy) | +15,500 | 15,500 | ||
| 2022-06-17 | Manning Paul B Director | Grant or award · Stock Option (right to buy) | +15,500 | 15,500 | ||
| 2022-04-06 | Alam Kamran Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-04-06 | PRASAD SUYASH CMO and Head of R&D | Grant or award · Employee Stock Option (right to buy) | +40,325 | 40,325 | ||
| 2022-02-23 | PRASAD SUYASH CMO and Head of R&D | Grant or award · Employee Stock Option (right to buy) | +80,650 | 80,650 | ||
| 2022-02-23 | Alam Kamran Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +80,000 | 80,000 | ||
| 2022-02-23 | Session R.A. II President and CEO | Grant or award · Employee Stock Option (right to buy) | +217,850 | 217,850 | ||
| 2022-02-03 | Manning Paul B Director | Purchase | +50,000 | $7.84 | $392K | 142,202 |
| 2022-02-03 | Manning Paul B Director | Purchase | +26,602 | $7.84 | $209K | 2,091,704 |
| 2022-02-02 | Manning Paul B Director | Purchase | +58,000 | $7.77 | $451K | 92,202 |
| 2022-02-02 | Manning Paul B Director | Purchase | +45,000 | $7.77 | $350K | 2,065,102 |
| 2022-02-02 | Manning Paul B Director | Purchase | +22,000 | $7.77 | $171K | 22,000 |
| 2022-02-02 | Nagendran Sukumar Director | Purchase | +10,000 | $8.01 | $80K | 29,226 |
| 2022-02-02 | Donenberg Phillip B. Director | Purchase | +3,000 | $7.78 | $23K | 3,000 |
| 2021-11-24 | Manning Paul B Director | Purchase | +2,202 | $13.19 | $29K | 34,202 |
| 2021-11-23 | Session R.A. II President and CEO | Purchase | +16,510 | $12.12 | $200K | 9,164,912 |
| 2021-11-23 | Session R.A. II President and CEO | Purchase | +26,008 | $12.65 | $329K | 9,190,920 |
| 2021-11-23 | Manning Paul B Director | Purchase | +20,000 | $12.54 | $251K | 32,000 |
Page 7 of 9 · 173 trades